Clinical Trial: A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

U.S., May 12 -- ClinicalTrials.gov registry received information related to the study (NCT07577843) titled 'A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease' on May 05.

Brief Summary: The purpose of this study is to assess how well JNJ-78934804 works (efficacy) and how safe it is (safety) as compared to guselkumab at Week 48 in participants with moderately to severely active Crohn's disease (a long-term, progressive [worsens with time] and life-threatening disease of the intestine).

Study Start Date: May 29

Study Type: INTERVENTIONAL

Condition: Crohn Disease

Intervention: DRUG: JNJ-78934804

JNJ-78934804 will be administered subcutaneously.

DRUG: Guselkumab

Guselkumab will be administered s...